在RAS野生型胰腺癌中的新治疗点
1Clinical Assistant Professor, Michigan State University/Henry Ford Health Sciences, 2800 W Grand Blvd, Detroit, MI, 48202, USA. mdiab2@hfhs.org.
Current treatment options in oncology
|November 15, 2024
概括
分子分析确定了晚期胰腺癌 (PDAC) 的新治疗途径. 针对性疗法在后续线路中更喜欢可操作的目标,而免疫疗法则保留给特定病例.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 精准医学是一门精准的医学.
背景情况:
- 晚期胰腺管腺癌 (PDAC) 治疗正在发展.
- 分子分析揭示了不同的患者子集,特别是KRAS野生型,具有治疗相关的基因组变化.
研究的目的:
- 讨论高级PDAC的不断变化的治疗环境.
- 突出分子分析和向治疗的作用.
- 概述基于分子标志物和患者健康状况的治疗选择的实用方法.
主要方法:
- 对所有新诊断的高级PDAC患者进行全面的分子分析.
- 利用针对性疗法在二线和超越的可操作目标.
- 考虑用于MSI-H/MMRd疾病的免疫疗法,具有战略序列.
主要成果:
- 向治疗显示出潜在的深度,持久的反应和在先进的PDAC中改善的生存率.
- MSI-H/MMRd PDAC患者可能不会像其他MSI-H/MMRd癌症那样从免疫治疗中受益.
- 对于具有可操作目标的患者,偏好针对性治疗而不是进一步的化疗.
结论:
- 分子分析对于指导先进的PDAC治疗至关重要.
- 针对性治疗是第二线及以上可操作目标的患者的首选选择.
- 治疗决策应整合分子发现,患者健康状况和患者偏好,并对免疫疗法等疗法进行战略序列.
相关概念视频
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


